News Releases

A simple set of decision-support tools combined with institutional buy-in can help increase the number of cancer patients who engage in treatment to help them quit tobacco, data from researchers in the Abramson Cancer Center at the University of Pennsylvania show.

Many elderly patients with metastatic renal cell carcinoma (RCC)—who are often underrepresented in clinical trials to treat the kidney cancer—are seeing overall survival benefits from treatment with targeted therapies, according to a new study from Penn Medicine researchers published this month in JAMA Network Open.

From understanding the genetics of cancer cells to improving cellular therapies and incorporating new methods of radiation therapy, a $12 million grant will help researchers at the Abramson Cancer Center at the University of Pennsylvania pursue the next generation of cancer treatments.

In largest study of its kind, Penn researchers compare overall adverse events of proton and photon therapies.

A specialized pain management program for patients who underwent robotic surgery for urologic cancers resulted in just eight percent going home with narcotics after discharge, compared to 100 percent who would have received them without this enhanced recovery protocol.

The Abramson Cancer Center at the University of Pennsylvania is establishing the Tara Miller Melanoma Center, which will focus on the accelerated development of novel therapies and improved clinical outcomes for patients with the deadliest form of skin cancer.

A new gift to support the Basser Center for BRCA at the University of Pennsylvania’s Abramson Cancer Center (ACC) established and endowed the Pearl Basser Professorship for BRCA-Related Research. Katherine L. Nathanson, MD, deputy director of the Abramson Cancer Center and director of genetics at the Basser Center, has been appointed the inaugural chair holder.

Switching pancreatic cancer patients to the PARP inhibitor rucaparib as maintenance therapy instead of continuing intensive chemotherapy either shrunk tumors or stopped them from growing in 17 of 19 patients in an interim analysis from a trial at the Abramson Cancer Center at the University of Pennsylvania.